Pierre-Antoine Gourraud

Pierre-Antoine Gourraud

Auto-generated profile, based on publicly available information

Pierre-Antoine Gourraud

Nantes Université

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ABAshley H Beecham
Ashley H Beecham
NPNikolaos A Patsopoulos
Nikolaos A Patsopoulos
DXDionysia K Xifara
Dionysia K Xifara
MDMary F Davis
Mary F Davis
AKAnu Kemppinen
Anu Kemppinen
JMJacob McCauley
Jacob McCauley
The International Multiple Sclerosis Genetics Consortium reports the discovery of 48 new susceptibility variants for multiple sclerosis through targeted follow-up of immune-related loci. They also report fine mapping of association signals at established susceptibility loci and provide insights into the immune system processes underlying this disease. Using the ImmunoChip custom genotyping array, we analyzed 14,498 subjects with multiple sclerosis and 24,091 healthy controls for 161,311 autosomal variants and identified 135 potentially associated regions (P < 1.0 × 10−4). In a replication phase, we combined these data with previous genome-wide association study (GWAS) data from an independent 14,802 subjects with multiple sclerosis and 26,703 healthy controls. In these 80,094 individuals of European ancestry, we identified 48 new susceptibility variants (P < 5.0 × 10−8), 3 of which we found after conditioning on previously identified variants. Thus, there are now 110 established multiple sclerosis risk variants at 103 discrete loci outside of the major histocompatibility complex. With high-resolution Bayesian fine mapping, we identified five regions where one variant accounted for more than 50% of the posterior probability of association. This study enhances the catalog of multiple sclerosis risk variants and illustrates the value of fine mapping in the resolution of GWAS signals.

27 July 2016 in Annals of Neurology
Verified
Journal Article
Open access
PDF file
UTUniversity of California, San Francisco MS-EPIC Team:
University of California, San Francisco MS-EPIC Team:
PMPhD Bruce A. C. Cree MD
PhD Bruce A. C. Cree MD
PGPierre-Antoine Gourraud
Pierre-Antoine Gourraud
JOJorge R. Oksenberg
Jorge R. Oksenberg
CBCarolyn Bevan
Carolyn Bevan
SHStephen L. Hauser
Stephen L. Hauser
Objective: To characterize the accrual of long‐term disability in a cohort of actively treated multiple sclerosis (MS) patients and to assess whether clinical and magnetic resonance imaging (MRI) data used in clinical trials have long‐term prognostic value.Methods: This is a prospective study of 517 actively managed MS patients enrolled at a single center.Results: More than 91% of patients were retained, with data ascertained up to 10 years after the baseline visit. At this last assessment, neurologic disability as measured by the Expanded Disability Status Scale (EDSS) was stable or improved compared to baseline in 41% of patients. Subjects with no evidence of disease activity (NEDA) by clinical and MRI criteria during the first 2 years had long‐term outcomes that were no different from those of the cohort as a whole. 25‐OH vitamin D serum levels were inversely associated with short‐term MS disease activity; however, these levels had no association with long‐term disability. At a median time of 16.8 years after disease onset, 10.7% (95% confidence interval [CI] = 7.2–14%) of patients reached an EDSS ≥ 6, and 18.1% (95% CI = 13.5–22.5%) evolved from relapsing MS to secondary progressive MS (SPMS).Interpretation: Rates of worsening and evolution to SPMS were substantially lower when compared to earlier natural history studies. Notably, the NEDA 2‐year endpoint was not a predictor of long‐term stability. Finally, the data call into question the utility of annual MRI assessments as a treat‐to‐target approach for MS care. Ann Neurol 2016;80:499–510

4 April 2008 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CBC. Bureau
C. Bureau
SMS. Metivier
S. Metivier
JPJ. M. Peron
J. M. Peron
JSJ. Selves
J. Selves
MRM. A. Robic
M. A. Robic
JVJ. P. Vinel
J. P. Vinel

21 November 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
NPNikolaos A. Patsopoulos
Nikolaos A. Patsopoulos
LBLisa F. Barcellos
Lisa F. Barcellos
RHRogier Q. Hintzen
Rogier Q. Hintzen
CSCatherine Schaefer
Catherine Schaefer
CDCornelia M. van Duijn
Cornelia M. van Duijn
PBPaul De Bakker
Paul De Bakker
The major histocompatibility complex (MHC) region is strongly associated with multiple sclerosis (MS) susceptibility. HLA-DRB1*15:01 has the strongest effect, and several other alleles have been reported at different levels of validation. Using SNP data from genome-wide studies, we imputed and tested classical alleles and amino acid polymorphisms in 8 classical human leukocyte antigen (HLA) genes in 5,091 cases and 9,595 controls. We identified 11 statistically independent effects overall: 6 HLA-DRB1 and one DPB1 alleles in class II, one HLA-A and two B alleles in class I, and one signal in a region spanning from MICB to LST1. This genomic segment does not contain any HLA class I or II genes and provides robust evidence for the involvement of a non-HLA risk allele within the MHC. Interestingly, this region contains the TNF gene, the cognate ligand of the well-validated TNFRSF1A MS susceptibility gene. The classical HLA effects can be explained to some extent by polymorphic amino acid positions in the peptide-binding grooves. This study dissects the independent effects in the MHC, a critical region for MS susceptibility that harbors multiple risk alleles. Multiple sclerosis (MS) is an inflammatory and neurodegenerative disease with a heritable component. Although it has been known for a long time that the strongest MS risk factor maps to the major histocompatibility complex (MHC) on chromosome 6, there are still many unresolved questions as to the identity and the nature of the risk variants within the MHC. Because the MHC has a complex structure, systematic investigation across this region has been challenging. In this study, we used state-of-the-art imputation methods coupled to statistical regression to query variants in the human leukocyte antigen (HLA) class I and II genes for a role in MS risk. Starting from available SNP genotype data, we replicated the strongest risk factor, the HLA-DRB1*15:01 allele, and were able to identify 11 independent effects in total. Functional studies are now needed to understand their mechanism in MS etiology.

21 June 2012 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
PGPierre‐Antoine Gourraud
Pierre‐Antoine Gourraud
HHHanne F. Harbo
Hanne F. Harbo
SHStephen L. Hauser
Stephen L. Hauser
SBSergio Baranzini
Sergio Baranzini

4 March 2010 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
EPE Puzenat
E Puzenat
VBV Bronsard
V Bronsard
SPS Prey
S Prey
PGP‐A Gourraud
P‐A Gourraud
SAS Aractingi
S Aractingi
FAFrançois Aubin
François Aubin